Company intelligence / Profile preview

Anatomic

Minneapolis, Minnesota, United Statesanatomic.com ↗

Ownership: Private
Employees: ~17
Development stage: Commercial

Overview

Anatomic has developed proprietary technology to rapidly generate human neural tissues from pluripotent stem cells, significantly reducing the time required to produce hiPSC-derived neurons from one month to one week. Their Primal Ectoderm Platform enables efficient production of sensory neurons, motor neurons, Schwann cell precursors, and melanocytes for use in basic neuroscience research and drug discovery targeting neurological conditions. No clinical trial results as they do not develop drugs directly.

Therapeutic areas: Neurology
Modalities: Cell therapy (hiPSC-derived neurons, Schwann cells, melanocytes)Differentiation kits (for cell production)
Industry: Non-Drug Biotech

Partnerships

University of MinnesotagBETA Medtech acceleratorMinnesota Department of Employment and Economic Development

Beyond the preview

Go deeper on Anatomic.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anatomic.

Explore the full profile